FXYD1 and Hypertension: Instead, it is only really genetic mutations for monogenic hypertension syndromes that are expected to have larger, clinically meaningful effect sizes for single mutation variants.50,51 Therefore, we suggest that the large effect size of this SNP for increasing BP levels within middle-aged men demonstrates the importance of the phospholemman/Na/K ATPase regulatory pathway in the overall control of BP.